Pure Global

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) - Trial NCT06297603

Access comprehensive clinical trial information for NCT06297603 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 320 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06297603
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06297603
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor

Study Focus

Type 2 Diabetes

Retatrutide

Interventional

drug

Sponsor & Location

Eli Lilly and Company

Sun City West,La Mesa,Torrance,Fleming Island,Idaho Falls,Topeka,Billings,Reno,Albany,Buffalo,Long Island City,Chapel Hill,Hickory,Cleveland,Tulsa,Pittsburgh,Bartlett,Dallas,Houston,Houston,Mesquite,S, Argentina,Puerto Rico,United Kingdom,United States of America

Timeline & Enrollment

Phase 3

Mar 15, 2024

Oct 09, 2026

320 participants

Primary Outcome

Change from Baseline in Hemoglobin A1c (HbA1c) (%)

Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared
 with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate
 glycemic control on basal insulin alone or a combination of basal insulin with or without
 metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about
 14 months and may include up to 22 visits.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06297603

Non-Device Trial